On the basis of the critical role that MET signaling plays in human cancer, various small molecule tyrosine kinase inhibitors (TKIs) that block the tyrosine phosphorylation of the catalytic domain of the receptor with subsequent arrest of downstream signal propagation are currently under clinical trials [19, 20]. This evidence concerns the gene MET and cancer.